MGMT and central nervous system cancer: The average percentage methylation of the MGMT gene promoter in the ultrasonic tissue fragments taken from the core of the tumor was comparable to the values for the diagnostic biopsy (mean percentage difference 1.5 ± 0.6%, n = 5 gliomas; Figure 2B and C).